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ABSTRACT
OBJECTIVE: To investigate the effect of Jianpijiedu
Fang (JPJDF) on phosphatase and tensin homolog
(PTEN), phosphoinositide 3-kinase (PI3K), and focal
adhesion kinase (FAK), and on the survival of hepa-
tocellular carcinoma (HCC) nude mice.
METHODS: Forty male nude mice were randomly
divided into 4 groups. Human HCC tissue was im-
planted in the livers of three groups. After 24 h, the
three groups were treated respectively with JPJDF
(37.5 g/kg), saline (20 mL/kg) and Tegafur (FT-207,
160 mg/kg) once a day for 10 weeks. The control
group without implanting the tissue was concur-
rently treated with saline (20 mL/kg). The survival
data and body weight of all mice were recorded,
and expression levels of PTEN, PI3K and FAK in nor-
mal tissue and cancer tissue of the livers were eval-
uated with immunohistochemical method.
RESULTS: The cumulative survival rate of the mice
in the JPJDF group was higher than those of the
other groups. The rate of weight loss was the low-
est in JPJDF group. The survivability and weight
loss rate in FT-207 group were the poorest in all
groups. The expression intensity of PTEN was high-
er in normal tissues than in cancer tissues, and low-
er in the normal tissues of HCC models than in that
of mice without HCC. The PTEN expression intensi-
ty in normal tissue and cancer tissue from mice
treated with FT-207 were lower than that from the
mice treated with JPJDF or saline. The expression in-
tensity of PI3K was higher in cancer tissue than in
normal tissue. The PI3K expression intensity was
the lowest in normal tissue and cancer tissue from
mice treated with JPJDF, and the intensity from
mice treated with FT-207 was the highest. In mice
treated with JPJDF, the expression intensity of FAK
was higher in the normal tissue and lower in the
cancer tissue than those of the other treatment
groups.
CONCLUSION: The mechanism accounting for the
prolonged survival of HCC-bearing mice treated
with JPJDF might be related to the reduction in
weight loss and the benign regulation of PTEN,
PI3K, and FAK.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
The survival of patients with advanced liver cancer is
poor.1,2 Traditional Chinese Medicine (TCM) has been
widely used to prolong the survival of tumor-bearing
patients with advanced liver cancer and is considered
to be a research hotspot in the treatment of malignant
tumors.3,4 Phosphatase and tensin homolog (PTEN) is
an important broad-spectrum tumor suppressor. Its ex-
pression level is low or absent in hepatoma cells.5,6 Fo-
cal adhesion kinase (FAK) activity is closely related to the
metastasis and invasion of liver cancer, and serves as an in-
dependent prognostic indicator of liver cancer.7,8 It has
been known that phosphoinositide 3-kinase (PI3K) sig-
naling plays an important role in the development of
liver cancer. Data supporting the role of PTEN as an
inhibitor of PI3K signalling through PtdIns (3, 4, 5) P5
phosphatase activity are overwhelming.9 This study fo-
cused on the effect of the Jianpijiedu Fang (JPJDF) on
the survival of mice with hepatocellular carcinoma.
MATERIALS ANDMETHODS
Animals
Forty BALB/c athymic male mice, 4-6 weeks old (Cer-
tificate of Conformity number: 0041294), were pur-
chased from the Experimental Animal Company of
Shang Hai Slaccas Experimental Animal Co. Ltd.,
Shanghai, China. They were raised in specific patho-
gen free (SPF) conditions in separate cages.
Medicinal and reagents
JPJDF (Application: CN101991807A) consisted of
Dangshen (Radix Codonopsis) 30 g, Fuling (Poria) 15 g,
Baizhu (Rhizoma Atractylodis Macrocephalae) 15 g, Ban-
zhilian (Herba Scutellariae Barbatae) 30 g, Ezhu (Rhi-
zoma Curcumae Phaeocaulis) 15 g, Chaihu (Radix Bu-
pleuri Chinensis) 10 g, and Gancao (Radix Glycyrrhizae)
6 g. It was prepared by the College of Pharmacy, the
Guangzhou University of Chinese Medicine. The pre-
pared herbal medicines were purchased from Guang-
zhou Medicinal Material Co. Ltd., Guangzhou, China.
and their quality met the requirements of the Pharma-
copoeia of the People's Republic of China. FT-207 was
supplied by the Bioengineering Co. Ltd. of Harbin
Pharmaceutical Group, Harbin, China, (batch num-
ber: 20070801). Bel-7402 hepatoma cells was pur-
chased from Experimental Animal Company of Shang
Hai Slaccas Experimental Animal Co. Ltd., Shanghai,
China. The rabbit anti-human PTEN polyclonal anti-
body (batch number 9559) were purchased from Cell
Signaling Technology, Inc., Shanghai, China, PI3K
polyclonal antibody (batch number 8553) were pur-
chased from Cell Signaling Technology, Inc., Shanghai,
China, and FAK monoclonal antibody (batch number
3285s) were purchased from Cell Signaling Technolo-
gy, Inc., Shanghai, China. SP Histostaining Reagent
(batch number 80924) was produced by the Wuhan
Boster Biological Technology Co. Ltd., Wuhan, China.
Instruments
Microtome: Leica DM3000: Lecia Camera AG, Solms,
Germany; Clean bench: Forma Co. Ltd., Losangeles,
CA, USA; Optical microscope: Olympus Optical Co.
Ltd., Tokyo, Japan; Inverted microscope: Chongqing
Guangxue instrument Co. Ltd., Chongqing, China;
Digital camera: Kodak (Japan); TS-8 decolorant cradle:
Jiangsu Haimen Qilinbeier Manufacturing Co. Ltd., Ji-
angsu, China; CU-420 electric-heated thermostatic wa-
ter bath: Shanghai Yiheng Science-Technique Co. Ltd.,
Shanghai, China; MC-1180 microscope: Guangzhou
Yuexian Optical instrument Co. Ltd., Guangzhou, Chi-
na; DS-28 electronic scale: Wuhan Automation instru-
ment plant, Wuhan, China; Ultra Pure UF laboratory
pure water system: Shanghai Hetai instrument Co.
Ltd., Shanghai, China. Image-pro plus 6.0 software (In-
ternational Business Machines Corporation, Armonk,
NY, USA): Department of Pathology, the First Affiliat-
ed Hospital of Sun Yat-sen University.
Animal grouping and model Establishment
Forty athymic mice were assigned randomly to A, B,
C, D groups, 10 for each. Three of them were used to
establish tumor models. The indirect orthotopicaltrans-
plantation was performed with the method by Sun et
al 10 The animals were inoculated with Bel-7402 hepa-
toma cells at a concentration of 1×107 cells/mL on the
waist and back. Once the subcutaneous transplantation
tumor reached the size of 1 cm in diameter, it was ex-
cised. Necrotic tissue was removed and the remaining
part was cut approximately into segments of 1 mm3 in
Hanks solution. For transplantation, the mouse was
anesthetized with pentobarbital (45 mg/kg weight); the
left upper quadrant of the abdominal cavity was trans-
versely incised to expose the liver; a bodkin pinhead
(20 angle of slope, 3 mm of depth) was used to imbed
1 piece of tumor tissue in the hepatic lobe parenchy-
ma; within 40 min after the tumor tissue had been dis-
sected, the incision was compressed to stop bleeding,
and the abdomen was closed.
Treatment
After model establishment, group A received intragas-
tric administration of JPJDF at a dose of 37.5 g/kg, qd;
group B received intragastric administration of saline
at a dose of 20 mL/kg, qd; group D received intragas-
tric administration of FT-207 at a dose of 160 mg/kg,
qd; group C as a parallel control without implanting tu-
mor issue was administered intragastrically with saline
at a dose of 20 mL/kg.
Variables measurement and procedure
The variables measured were survival time; weight loss
rate=100×(terminal body weight－ verage weight dur-
ing the experiment)/(average weight during the exper-
iment)
Volume rate of liver cancer=(volume of liver cancer)/
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(terminal bodyweight), and average optical density
(AOD)=100× (integral optical densit)/(picture area).
(the expression intensity of PTEN/PI3K/FAK in nor-
mal tissue and tumor tissue of livers).
The survival data and weight of each mouse were docu-
mented during the process of observation. Dying mice
were sacrificed and dissected. The normal tissue and
cancer tissue were fixed in 4% neutral formalin for par-
affin embedding, and microtome sections (4-μm-thick
serial sections) were fixed on siliconized glass slides.
Immunohistochemical slides: 4-μm-thick paraffin sec-
tions were baked at 65℃ for deparaffinization and hy-
dration, incubated in 3% hydrogen peroxide for 5-
10 min to inactivate endogenous peroxidase, micro-
waved to repair the antigen and blocked with 10% nor-
mal goat serum. PTEN/ FAK and PI3K antibodies (1∶
100) were incubated overnight at 4℃ . Then the slides
were washed with PBS for 2 min 3 times. Next, goat
anti-rabbit IgG antibody-HRP multimer (Cell Signal-
ing Technology, Inc.) was added drop-wise, and the
slides were incubated for approximately 30 min at
37℃ , then washed with PBS for 2 min 3 times. DBA
was added, and the slides were washed thoroughly with
distilled water. In parallel, PBS was used as negative
control.
One HE slide and one immunohistochemical slide
were prepared for each specimen. All pictures were col-
lected with a color-cooled CCD system (Leica DM
3000 microscope system: color-cooled CCD, physical
resolution 2048×2560, pixel size 2.78 mm×2.78 mm).
Five fields of view of each slide were collected at 400×
magnification, and 1 field of view of each slide was col-
lected at 50× magnification. The immunohistochemi-
cal expression intensities of PTEN, PI3K and FAK
were analyzed with the Image-Pro Plus 6.0 software at
400× magnification.
Statistical analysis
SPSS 17.0 (IBM, NY, USA) was used to process data.
Kaplan-Meier method was used for survival analysis;
ANOVA and the rank-sum test were used for normally
and non-normally distributed data, respectively.There
are statistically significant in P<0.05.
RESULTS
Survivability
The cumulative survival rates showed that treatment
with JPJDF at a dose of 37.5 g/kg could significantly
prolong the survival of the tumor-bearing mice. By the
Tarone-Ware test, A vs B, χ2=6.54, P=0.011; A vs C: χ2=
3.86,P=0.049; A vsD,χ2=16.55,P=0.000 (Figure 1).
Comparison of median survival times: by the Krus-
kal-Wallis test, χ2=14.80, P=0.002; by the Mann-Whit-
ney test, A vs B: Z=-1.988, P=0.047; A vs C: Z=-2.70,
P=0.007; A vs D: Z=-3.63, P=0.000; and the compari-
sons of other groups showed no significant difference
(Figure 1).
Weight loss rates and volume rates of liver cancer
There were significant differences in the weight loss
rates among the groups (Table 1). One-way ANOVA,
F=3.82, P=0.018; A vs B, P=0.028, A vs C, P=0.005; A
vs D, P=0.009. There was no significant difference be-
tween groups in the volume rate of liver cancer, F=
2.38, P=0.112 (Table 1).
AOD of PTEN, PI3K and FAK
PTEN, PI3K and FAK were localized to the cyto-
plasm of normal liver and liver cancer cells, and the
expression intensities of PTEN, PI3K and FAK were
higher in normal liver tissues than in liver cancer tis-
sues (Figure 2).
Analysis of AOD of PTEN
Liver tissue vs tumor mass: Mann-Whitney test, for A,
Z=-6.53, P=0.000; for B, Z=-5.56, P=0.000; for D,
Z=-6.82, P=0.000. AOD of PTEN in the livers of each
group: by the Kruskal-Wallis test, χ2=60.47, P=0.000;
by the Mann-Whitney test, A vs C, Z=-5.95, P=0.000;
A vs D, Z=-2.92, P=0.004; B vs D, Z=-2.55, P=0.011;
B vs C, Z=-4.79, P=0.000; C vs D, Z=-6.93, P=0.000.
AOD of PTEN in the liver cancers of each group:
Kruskal-Wallis test: χ2=34.21, P=0.000; Mann-Whit-
ney test: A vs D, Z=-3.95, P=0.000; B vs D, Z=-5.86,
P=0.000 (Table 2).
Analysis of the AOD of FAK
Liver tissue vs tumor mass: by the Mann-Whitney test,
for A, Z=-7.40, P=0.000; for B, Z=-7.29, P=0.000; for
D, Z=-6.71, P=0.000. The AOD of FAK in the liver
tissue of each group: by the Kruskal-Wallis test, χ2=
18.62, P=0.000; by the Mann-Whitney Test, A vs B:
Z=-3.49, P=0.000; A vs C: Z=-3.18, P=0.001; A vs D:
Z=-3.35, P=0.001. The AOD of FAK in the liver can-
cer of each group: by the Kruskal-Wallis test: χ2=36.71,
P=0.000; by the Mann-Whitney test: A vs B: Z=-5.53,
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Figure 1 Kaplan-Meier estimates cum survival of different
groups
A: model group received JPJDF at a dose of 37.5 g/kg; B:
model group received saline; C: normal group; D: model
group received FT-207. Tarone-Ware χ2=16.01, P=0.001.
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P=0.000; A vs D: Z=-5.07, P=0.000 (Table 2).
Analysis of the AOD of PI3K
Liver tissue vs tumor mass: by the Mann-Whitney test,
for A, Z=-3.44, P=0.001; for B, Z=-3.78, P=0.000; for
D, Z=-3.78, P=0.000. The AOD of PI3K in the liver
tissue of each group: by the Kruskal-Wallis test: χ2=
27.08, P=0.000; by the Mann-Whitney Test, A vs B:
Z=-2.04, P=0.041; A vs C: Z=-2.23 P=0.026; A vs D:
Z=-3.44, P=0.001. B vs C: Z=-0.076, P=0.94, B vs D:
Z=-2.27, P=0.023, C vs D: Z=-2.39, P=0.01. The
AOD of PI3K in the liver cancer of each group: by the
Kruskal-Wallis test: χ2=22.5, P=0.000; by the
Mann-Whitney test: A vs B: Z=-3.33, P=0.001; A vs
D: Z=-3.78, P=0.000; B vs D: Z=-3.21, P=0.001.
Analysis of the correlation between PTEN and PI3K
In liver normal tissue, the correlation coefficient r
was -0.911 (P=0.001); in liver cancer tissue, r
was -0.824 (P=0.011).There was a negative correlation
between the expression of PI3K and PTEN.
DISCUSSION
Traditional Chinese Medicine (TCM) is considered an
alternative treatment for liver cancer. The uniqueness
E F G H
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Figure 2 The expression of PTEN/ PI3K/ FAK in normal liver tissue and cancer tissue of model group received JPJDF
A: The expression of PTEN of liver tissue (×10); B: The expression of PTEN of liver tissue (×40); C: The expression of PTEN of cancer
tissue (×10); D: The expression of PTEN of cancer tissue (×40); E: Negative control of liver tissue (×10); F: Negative control of liver
tissue (×40); G: Negative control of cancer tissue (×10); H: Negative control of cancer tissue (×40); I: The expression of FAK of liver
tissue (×10); J: The expression of FAK of liver tissue (×40); K: The expression of FAK of cancer tissue (×10); L: The expression of FAK
of cancer tissue (×40); M: The expression of PI3K of liver tissue (×10); N: The expression of PI3K of liver tissue (×40); O: The expres-
sion of PI3K of cancer tissue (×10); P: The expression of PI3K of cancer tissue. PTEN: phosphatase and tensin homolog; PI3K: phos-
phoinositide 3-kinase; FAK: focal adhesion kinase; JPJDF: jianpijiedu Fang. Dyeing method of all pictures are the Immunohisto-
chemical SP method, PBS was used as negative control. All pictures are selected from the model group received JPJDF at dose of
37.5 g/kg.
Notes: A: model group received JPJDF at a dose of 37.5 g/kg; B: model group received saline; C: normal group; D: model group received
FT-207. Compared with A, aP<0.05, bP<0.01.
Group
Weight loss rate (%)
Volume rate of liver cancer (mm3/g)
n
10
10
A
-7±16
55±42
B
-20±10a
29±25
C
-23±14b
-
D
-22±7b
27±26
Table 1Weight loss rates and volume rates in liver cancer of different groups ( xˉ ±s)
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of TCM is that it focuses on the systemic regulation of
body functions achieved by syndrome differentiation.
In this regard, TCM is a kind of individualized treat-
ment. Clinical practice and experience suggested that
patients' conditions with liver cancers and other malig-
nant tumors could be systemically improved with
TCM. These patients could achieve remission and even
longer survival.
JPJDF has been used for liver cancers. Its efficacy was
attributable to two factors: one was, in terms of TCM
theory, strengthening the spleen and replenishing Qi
with Dangshen (Radix Codonopsis), Fuling (Poria), Bai-
zhu (Rhizoma Atractylodis Macrocephalae) and Gancao
(Radix Glycyrrhizae); the other was the detoxifying and
mass-dissipating effect underpinned by Banzhilian
(Herba Scutellariae Barbatae), Ezhu (Rhizoma Curcum-
ae phaeocaulis), Chaihu (Radix Bupleuri Chinensis).
From the perspective of TCM, it is believed that weak
spleen function may lead to excessive liver Qi. In that
case, Qi tends to be stagnant, which induces weak
blood circulation. This may result in stagnant blood
and phlegm nodules formation. The condition allows
harmful pathogens to gain stronghold in the body.
Strengthening the spleen and replenishing Qi, on one
hand, can promote the body's ability to digest and uti-
lize nutrients and on the other hand, counteract the ex-
cessive liver Qi. Baizhu (Rhizoma Atractylodis Macro-
cephalae) plays the role in clearing pathogens; Chaihu
(Radix Bupleuri Chinensis) plays a role in soothing liver
and regulating Qi; Ezhu (Rhizoma Curcumae phaeocau-
lis) was able to dissipate phlegm nodules in the body.
Thus, JPJDF could potentially inhibit the growth of
the tumor.
This study revealed that JPJDF could improve the sur-
vival of the mice compared with the chemotherapy
group, saline group, and control group. This suggested
that the efficacy of JPJDF in treating liver cancer lay in
regulating and improving the holistic functioning of
the body. In addition, the weight loss rate results
showed that JPJDF could maintain the weight of the
mice. Furthermore, the animals could resist tumor in-
vasion, thereby improve the tumor-bearing mice surviv-
al. JPJDF had no effect, however, on tumor volume
rate. This might suggest that maintained was a relative-
ly stable proportion of the tumor volume to a mouse
body.
PTEN was identified as a potent tumor suppressor that
was frequently mutated or deleted in many cancers in-
cluding HCC. PTEN expression and activity appear to
be regulated by numerous and complex mechanisms.
In addition to the epigenetic changes induced by the
methylation or deacetylation of PTEN precursors,
many transcription factors can positively or negatively
regulate its expression. Recent evidence also indicates
that post-transcriptional repression and protein modifi-
cation of PTEN mRNA are regulated by a series of mi-
croRNAs.11 Proteins such as FAK can also affect the sta-
bility of PTEN.12 Recent developments call for a
re-evaluation of the oncogenic mechanisms behind
PI3K pathway alteration, and a PTEN-suppressing tu-
mor might be associated with repressing the activity of
PI3K and cell proliferation.13 The results of one study
demonstrated that PTEN plays fundamental role in
maintaining chromosomal stability and controlling
DNA repair.14 It was also reported that the activity of
PTEN was involved in stabilizing E-cadherin/β-catenin adherens junctional complexes and cell-cell
contacts and suppressing invasiveness.15 Some data
have demonstrated that dietary unsaturated fatty acids
promoted hepatoma progression by reducing the ex-
pression of PTEN.16 In conclusion, the regulatory
mechanisms of PTEN are complex, especially in rela-
tion to liver cancer.
Our results revealed that PTEN was found in the cyto-
plasm of normal liver cells and cancer liver cells.
PTEN expression was significantly decreased in hepato-
cellular carcinoma; the expression levels of PTEN in
the livers of cancerous mice were obviously lower than
in those of the non-cancerous mice. The lowest expres-
sion level of PTEN was found in both the normal tis-
sue and cancer tissue of the FT-207 group. This group
also had the lowest survival rate, demonstrating that
Group
PTEN in liver
PTEN in cancer
FAK in liver
FAK in cancer
PI3K in liver
PI3K in cancer
n
10
10
10
10
10
10
A
3.6±2.1
0.8±1.0a
5.3±1.3
1.0±0.7
0.8±0.3a
3.7±0.8
B
4.0±2.8b
0.7±0.6a
4.4±1.2c
2.1±0.8 c
1.3±0.6d
4.4±1.0ca
C
7.0±2.0c
-
4.6±0.9d
-
1.3±0.5d
-
D
2.5±2.1db
0.2±0.2
4.2±1.5d
2.0±0.9 c
2.7±0.7cb
5.6±1.1c
Table 2 The AODs of PTEN, PI3K and FAK in liver and cancer tissues of different groups ( xˉ ±s)
Notes: A: model group received JPJDF at a dose of 37.5 g/kg; B: model group received saline; C: normal group; D: model group received
FT-207. AODs: average optical density; PTEN: phosphatase and tensin homolog; PI3K: phosphoinositide 3-kinase; FAK: focal adhesion
kinase. Compared with A: cP<0.001, dP<0.05; compared with C, bP<0.001; compared with D, aP<0.001.
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the tumor suppressor ability of PTEN had decreased se-
verely in these mice with liver cancer and suggesting
that FT-207 damaged the body's anti-cancer function.
Compared with the FT-207 group, the JPJDF group
maintained their expression level of PTEN as high as
that of the saline-treated group. Due to the complexity
of the structural components of the JPJDF, its effect on
multi-targets and the uncertainty in its pharmacokinet-
ics, PTEN expression may be insufficient to address
the mechanism underlying the JPJDF's anti-hepatoma
action.
FAK, a crucial mediator of integrin and growth factor
signaling, is a novel and promising target in cancer
therapy. FAK over-expression can significantly change
the local cells' adhesion ability and promote cancer cell
proliferation, invasion and metastasis.17 This is impor-
tant for the progression and metastasis of liver cancer,
and over-expression of FAK is closely related to the de-
velopment and malignancy of liver cancer.18 Our study
showed that FAK was identified in the cytoplasm of
the normal cells and cancer cells. The expression level
of FAK in the cancer tissue was substantially lower
than that in normal tissue, which suggested that FAK
might play an important role in maintaining liver's
physiological function because the physiological func-
tion of the cancer tissue was severely inhibited. As de-
tected by vigorous karyokinesis, squeezed cytoplasm
and reduced organelles, a decreased expression level of
FAK was observed. In the cancer tissue, the expression
of FAK in the JPJDF group markedly increased, while,
the expression level was lower than those in the saline
group and FT-207 group. Therefore, additional studies
are required to explore the mechanisms behind this
phenomenon.
In vertebrates, the tumor suppressor PTEN regulates
many cellular processes through its Ptdlns (3, 4, 5) P3
lipid phosphatase activity to antagonize PI3K signal-
ing.19,20 PI3K pathway exerts its influence on its down-
stream molecule AKT to regulate various cell functions
including proliferation, transformation, apoptosis, and
angiogenesis. PTEN is an inhibitor of PI3K, and its
loss or mutation is common in human cancers.21 Our
results suggested that PI3K was found in the cytoplasm
of liver normal cells and cancer cells. PI3K expression
was significantly increased in hepatocellular carcinoma,
suggesting that the over-expression of PI3K might be
closely related to tumor formation. The lowest expres-
sion level of PI3K was found in the normal tissue and
cancer tissue of the JPJDF group. We also found a neg-
ative correlation between the expression of PI3K and
the expression of PTEN. This result implied that
PTEN played an anti-cancer role dependent on its neg-
ative regulation of PI3K signaling, and that JPJDF
might play a role in down-regulating PI3K. The expres-
sion levels of PI3K in the normal tissue and cancer tis-
sue in the FT-207 group were obviously higher than
those in the other groups. This suggested that FT-207
could reduce anti-cancer effect not only by inhibiting
PTEN expression, but also by over-expressing PI3K.
In conclusion, JPJDF could improve the survival of tu-
mor-bearing mice implanted with HCC by reducing
weight loss and benignly regulating PTEN, PI3K, and
FAK.
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